Select Page

Injectables offer maximum bioavailability of drugs towards the intended site of action and avoid the first pass metabolism. The injectable route is mostly preferred for the drugs which can’t be taken orally or have some stability problems. Unconscious patients or patients having low compliance towards oral tablets or capsules can be preferred for the injectable drug delivery therapy.

Get Exclusive Sample Report at:

Market Dynamics

Increasing prevalence of chronic diseases such as diabetes, cardiac diseases, and anaphylaxis has supported growth of global injectable drug delivery market. According to the Allergy, Asthma & Clinical Immunology, in 2015, around 15 million people suffered from food allergies in the U.K. Similarly, according to the European Academy of Allergy and Clinical Immunology (EAACI), in 2015, around 17 million people suffered from food allergies in the U.K., of which around 3.5 million were children. Increasing awareness regarding safety and concern of needlestick injuries is a major factor driving growth of the injectable drug delivery market.

For instance, the WHO recommended the use of safety syringes with sharp injury protection (SIP), in order to prevent needlestick injuries. Similarly, in May 2017, Innovative Neurons LLC announced to commercialize its patented auto retractable multi-needle syringe known as FAST (fast, accessible, safe, and technology) to decrease needlestick injuries. Various market players are focusing on the development and advancement in this space. For instance, ACT-O-VIAL System offered by Pfizer Inc. is a dual-component vial system that allows reconstitution of sterile, injectable medications by pressing on the plastic cap. The facility launch by market players to cater requirements of patients is expected to drive the market growth. For instance, in July 2018, Pfizer, Inc. announced to build sterile injectable pharmaceutical production facilities in the Michigan, U.S.

Key companies covered as a part of this study include, Becton, Dickinson and Company, Pfizer Inc., Novo Nordisk A/S, Gerresheimer AG, Carl-Zeiss-Stiftung, Terumo Corporation, Vetter Pharma-Fertigung GmbH & Co. KG, SHL Group, Owen Mumford Limited, Injex Pharma GmbH.

Detailed Segmentation:

Global Injectable Drug Delivery Market, By Device Type:
Prefilled Syringes
Auto Injectors
Conventional Syringes

Global Injectable Drug Delivery Market, By Material Type:

Global Injectable Drug Delivery Market, By Usability:

Global Injectable Drug Delivery Market, By Route of Administration:

Global Injectable Drug Delivery Market, By End User:
Ambulatory Surgical Centers
Home Care Settings

Global Injectable Drug Delivery Market, By Region:
North America
Asia Pacific
Latin America
Middle East

Increasing Prevalence Of Chronic Diseases Such As Diabetes And Anaphylaxis Is Expected To Propel Growth Of The Global Injectable Drug Delivery Market

Increasing prevalence of chronic diseases such as diabetes and other diseases is expected to drive the market growth. According to the World Health Organization (WHO), in November 2011, around 60 million people in Europe suffered from diabetes, of which around 10.3% were men and 9.6% were women aged 25 years and above. Similarly, according to World Health Organization (WHO) 2018 factsheet, around 8.5% adults aged 18 years and above had diabetes in 2014 globally.

Moreover, the market players are focused on product development and launch of injectors, which is expected to propel growth of the global injectable drug delivery market over the forecast period. For instance, in 2016, Berlin-Chemie launched BerliPen areo 3 in Germany. BerliPen areo 3 is a 300 unit insulin pen, which can be used with six different insulins in the treatment of type 1 and 2 diabetes. Similarly, in August 2018, Teva Pharmaceuticals received the U.S. Food and Drug Administration (FDA) approval for generic version of Mylan’s EpiPen and EpiPen Jr. Teva Pharmaceuticals is the first generic manufacturer that received the FDA approval.

Request For Customization of Research Report @

Increasing Product Approval And Launch In North America Is Expected To Bolster The Market Growth

North America holds dominant position in the global injectable drug delivery market, owing to increased focus of regional players in research and development and product launches. In 2017, Bayer received U.S. Food and Drug Administration (FDA) approval for a connected auto-injector-BETACONNECT for relapsing-remitting multiple sclerosis medication and companion app- myBETAapp. The app allows patients to automatically have a record of all their injections and share that record with their nurse or physician. Similarly, in October 2018, Genentech announced the U.S. Food and Drug Administration (FDA) approval for single-dose prefilled syringes (PFS) for Xolair (omalizumab) as an additional formulation for both allergic asthma and chronic idiopathic urticaria (CIU) indications.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702